Oryzon Genomics Valuation
Is ORY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ORY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ORY's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ORY's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ORY?
Key metric: As ORY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ORY's PS Ratio? | |
|---|---|
| PS Ratio | 6.5x |
| Sales | US$15.83m |
| Market Cap | US$102.12m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7x |
| Enterprise Value/EBITDA | 1202.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ORY's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.9x | ||
BST Biotechnology Assets | 6.5x | n/a | €21.9m |
PHM Pharma Mar | 7.7x | 26.0% | €1.3b |
GRF Grifols | 1x | 6.0% | €6.6b |
PANG Pangaea Oncology | 4.2x | 4.4% | €61.0m |
ORY Oryzon Genomics | 6.5x | 61.7% | €98.1m |
Price-To-Sales vs Peers: ORY is expensive based on its Price-To-Sales Ratio (6.5x) compared to the peer average (4.9x).
Price to Sales Ratio vs Industry
How does ORY's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ORY is good value based on its Price-To-Sales Ratio (6.5x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is ORY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.5x |
| Fair PS Ratio | 10.7x |
Price-To-Sales vs Fair Ratio: ORY is good value based on its Price-To-Sales Ratio (6.5x) compared to the estimated Fair Price-To-Sales Ratio (10.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.56 | €6.27 +302.2% | 66.3% | €12.00 | €2.30 | n/a | 3 |
| Nov ’25 | €1.64 | €6.27 +282.6% | 66.3% | €12.00 | €2.30 | n/a | 3 |
| Oct ’25 | €1.81 | €6.27 +245.8% | 66.3% | €12.00 | €2.30 | n/a | 3 |
| Sep ’25 | €1.78 | €6.62 +271.5% | 60.9% | €12.00 | €2.30 | n/a | 3 |
| Aug ’25 | €1.81 | €6.69 +269.9% | 59.2% | €12.00 | €2.50 | n/a | 3 |
| Jul ’25 | €1.80 | €6.70 +272.1% | 59.1% | €12.00 | €2.50 | n/a | 3 |
| Jun ’25 | €1.99 | €6.69 +236.4% | 59.1% | €12.00 | €2.50 | n/a | 3 |
| May ’25 | €1.96 | €6.68 +240.6% | 59.3% | €12.00 | €2.50 | n/a | 3 |
| Apr ’25 | €1.72 | €6.84 +298.3% | 55.4% | €12.00 | €3.00 | n/a | 3 |
| Mar ’25 | €1.75 | €6.84 +291.0% | 55.4% | €12.00 | €3.00 | n/a | 3 |
| Feb ’25 | €1.88 | €6.85 +263.7% | 55.4% | €12.00 | €3.00 | n/a | 3 |
| Jan ’25 | €1.89 | €7.89 +317.6% | 65.3% | €15.00 | €3.00 | n/a | 3 |
| Dec ’24 | €2.06 | €7.89 +283.7% | 65.3% | €15.00 | €3.00 | n/a | 3 |
| Nov ’24 | €2.04 | €7.89 +287.5% | 65.3% | €15.00 | €3.00 | €1.64 | 3 |
| Oct ’24 | €2.05 | €8.41 +311.4% | 59.1% | €15.00 | €3.00 | €1.81 | 3 |
| Sep ’24 | €2.08 | €8.41 +304.5% | 59.1% | €15.00 | €3.00 | €1.78 | 3 |
| Aug ’24 | €2.08 | €8.41 +305.5% | 59.1% | €15.00 | €3.00 | €1.81 | 3 |
| Jul ’24 | €2.11 | €11.50 +445.0% | 30.4% | €15.00 | €8.00 | €1.80 | 2 |
| Jun ’24 | €2.06 | €11.50 +459.6% | 30.4% | €15.00 | €8.00 | €1.99 | 2 |
| May ’24 | €2.12 | €11.50 +442.5% | 30.4% | €15.00 | €8.00 | €1.96 | 2 |
| Apr ’24 | €2.24 | €11.50 +413.4% | 30.4% | €15.00 | €8.00 | €1.72 | 2 |
| Mar ’24 | €2.38 | €8.83 +271.9% | 53.6% | €15.00 | €3.50 | €1.75 | 3 |
| Feb ’24 | €2.53 | €8.83 +249.1% | 53.6% | €15.00 | €3.50 | €1.88 | 3 |
| Jan ’24 | €2.48 | €8.83 +256.2% | 53.6% | €15.00 | €3.50 | €1.89 | 3 |
| Dec ’23 | €2.12 | €8.83 +317.7% | 53.6% | €15.00 | €3.50 | €2.06 | 3 |
| Nov ’23 | €2.17 | €8.83 +307.1% | 53.6% | €15.00 | €3.50 | €2.04 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.